Charter Renewal of the Advisory Committee on Blood and Tissue Safety and Availability, 67920-67921 [2022-24610]
Download as PDF
<![CDATA[
67920
Federal Register / Vol. 87, No. 217 / Thursday, November 10, 2022 / Notices
FOR FURTHER INFORMATION CONTACT:
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
[Document Identifiers: CMS–10821]
Agency Information Collection
Activities: Submission for OMB
Review; Comment Request
Centers for Medicare &
Medicaid Services, Health and Human
Services (HHS).
ACTION: Notice.
AGENCY:
The Centers for Medicare &
Medicaid Services (CMS) is announcing
an opportunity for the public to
comment on CMS’ intention to collect
information from the public. Under the
Paperwork Reduction Act of 1995
(PRA), federal agencies are required to
publish notice in the Federal Register
concerning each proposed collection of
information, including each proposed
extension or reinstatement of an existing
collection of information, and to allow
a second opportunity for public
comment on the notice. Interested
persons are invited to send comments
regarding the burden estimate or any
other aspect of this collection of
information, including the necessity and
utility of the proposed information
collection for the proper performance of
the agency’s functions, the accuracy of
the estimated burden, ways to enhance
the quality, utility, and clarity of the
information to be collected, and the use
of automated collection techniques or
other forms of information technology to
minimize the information collection
burden.
SUMMARY:
Comments on the collection(s) of
information must be received by the
OMB desk officer by December 12, 2022.
ADDRESSES: Written comments and
recommendations for the proposed
information collection should be sent
within 30 days of publication of this
notice to www.reginfo.gov/public/do/
PRAMain. Find this particular
information collection by selecting
‘‘Currently under 30-day Review—Open
for Public Comments’’ or by using the
search function.
To obtain copies of a supporting
statement and any related forms for the
proposed collection(s) summarized in
this notice, please access the CMS PRA
website by copying and pasting the
following web address into your web
browser: https://www.cms.gov/
Regulations-and-Guidance/Legislation/
PaperworkReductionActof1995/PRAListing.
lotter on DSK11XQN23PROD with NOTICES1
DATES:
VerDate Sep<11>2014
17:43 Nov 09, 2022
Jkt 259001
William Parham at (410) 786–4669.
SUPPLEMENTARY INFORMATION: Under the
Paperwork Reduction Act of 1995 (PRA)
(44 U.S.C. 3501–3520), federal agencies
must obtain approval from the Office of
Management and Budget (OMB) for each
collection of information they conduct
or sponsor. The term ‘‘collection of
information’’ is defined in 44 U.S.C.
3502(3) and 5 CFR 1320.3(c) and
includes agency requests or
requirements that members of the public
submit reports, keep records, or provide
information to a third party. Section
3506(c)(2)(A) of the PRA (44 U.S.C.
3506(c)(2)(A)) requires federal agencies
to publish a 30-day notice in the
Federal Register concerning each
proposed collection of information,
including each proposed extension or
reinstatement of an existing collection
of information, before submitting the
collection to OMB for approval. To
comply with this requirement, CMS is
publishing this notice that summarizes
the following proposed collection(s) of
information for public comment:
1. Type of Information Collection
Request: New collection (Request for a
new OMB control number); Title:
Supplemental to Form CMS–2552–10;
Payment Adjustment for Domestic
NIOSH-Approved Surgical N95
respirators; Use: This supplemental
form supports the policy goal of
ensuring that quality PPE is available to
health care personnel when needed by
maintaining production levels of wholly
domestically-made PPE, a policy goal
emphasized in the National Strategy for
a Resilient Public Health Supply Chain,
published in July 2021 as a deliverable
of President Biden’s Executive Order
14001 on ‘‘A Sustainable Public Health
Supply Chain.’’ The supplemental form
calculates a payment adjustment for an
1886(d) hospital and/or a hospital paid
for outpatient services under the
hospital outpatient prospective payment
system (OPPS) purchasing domestic
NIOSH-approved surgical N95
respirators (domestic respirators)
effective for cost reporting periods
beginning on or after January 1, 2023. A
hospital eligible for the payment
adjustment must complete this
supplemental form and submit the form
with its Medicare cost report that covers
the same cost reporting period.
This information collection request is
associated with the final rule CMS–
1772–FC (RIN: 0938–AU82) that
displayed at the Federal Register on
November 3, 2022, and is scheduled for
publication on November 23, 2022.
Form Number: CMS–10821 (OMB
Control Number: 0938–TBD);
PO 00000
Frm 00066
Fmt 4703
Sfmt 4703
Frequency: Annually; Affected Public:
Private Sector (Business or other forprofit and not-for-profit institutions);
Number of Respondents: 4,662; Number
of Responses: 4,662; Total Annual
Hours: 2,331. (For policy questions
regarding this collection contact Gail
Duncan at 410–786–7278.)
Dated: November 7, 2022.
William N. Parham, III,
Director, Paperwork Reduction Staff, Office
of Strategic Operations and Regulatory
Affairs.
[FR Doc. 2022–24612 Filed 11–9–22; 8:45 am]
BILLING CODE 4120–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Charter Renewal of the Advisory
Committee on Blood and Tissue Safety
and Availability
Office of the Assistant
Secretary for Health, Office of the
Secretary, Department of Health and
Human Services.
AGENCY:
ACTION:
Notice.
The Department of Health and
Human Services is hereby giving notice
that the charter for the Advisory
Committee on Blood and Tissue Safety
and Availability (ACBTSA) has been
renewed.
SUMMARY:
FOR FURTHER INFORMATION CONTACT:
James Berger, Designated Federal Officer
for the TBDWG; Office of Infectious
Disease and HIV/AIDS Policy, Office of
the Assistant Secretary for Health,
Department of Health and Human
Services, Tower Building, 1101 Wootton
Parkway, Rockville, MD 20852. Phone:
(202) 795–7608. Email: ACBTSA@
hhs.gov.
The
ACBTSA is a non-discretionary federal
advisory committee. The ACBTSA is
authorized under 42 U.S.C. 217a,
Section 222 of the Public Health Service
(PHS) Act, as amended. The Committee
is governed by the provisions of the
Federal Advisory Committee Act
(FACA), Public Law 92–463, as
amended (5 U.S.C. App), which sets
forth standards for the formation and
use of advisory committees. The
ACBTSA advises, assists, consults with,
and makes policy recommendations to
the Secretary, through the Assistant
Secretary for Health, regarding broad
responsibilities related to the safety of
blood, blood products, tissues, and
organs. For solid organs and blood stem
cells, the Committee’s work is limited to
policy issues related to donor derived
SUPPLEMENTARY INFORMATION:
E:\FR\FM\10NON1.SGM
10NON1
Federal Register / Vol. 87, No. 217 / Thursday, November 10, 2022 / Notices
infectious disease complications of
transplantation.
To carry out its mission, the ACBTSA
provides advice to the Secretary through
the Assistant Secretary for Health on a
range of policy issues which includes:
(1) identification of public health issues
through surveillance of blood and tissue
safety issues with national biovigilance
data tools; (2) identification of public
health issues that affect availability of
blood, blood products, and tissues; (3)
broad public health, ethical, and legal
issues related to the safety of blood,
blood products, and tissues; (4) the
impact of various economic factors (e.g.,
product cost and supply) on safety and
availability of blood, blood products,
and tissues; (5) risk communications
related to blood transfusion and tissue
transplantation; and (6) identification of
infectious disease transmission issues
for blood, organs, blood stem cells and
tissues.
On September 29, 2022, the Secretary
approved for the ACBTSA charter to be
renewed. The new charter was filed
with the appropriate Congressional
committees and the Library of Congress
on October 9, 2022. Renewal of the
Committee’s charter gives authorization
for the Committee to continue to operate
until October 9, 2024.
A copy of the ACBTSA charter is
available on the Committee’s website at
https://www.hhs.gov/oidp/advisorycommittee/blood-tissue-safetyavailability/charter/.
Dated: November 2, 2022.
James J. Berger,
DFO, Advisory Committee on Blood and
Safety and Availability, Office of HIV/AIDS
and Infectious Disease Policy.
[FR Doc. 2022–24610 Filed 11–9–22; 8:45 am]
BILLING CODE 4150–41–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Notice of Meeting for the
Interdepartmental Substance Use
Disorders Coordinating Committee
(ISUDCC)
Substance Abuse and Mental
Health Services Administration
(SAMHSA), Department of Health and
Human Services (HHS).
ACTION: Notice.
lotter on DSK11XQN23PROD with NOTICES1
AGENCY:
The Secretary of Health and
Human Services (Secretary) announces
a meeting of the Interdepartmental
Substance Use Disorders Coordinating
Committee (ISUDCC).
SUMMARY:
VerDate Sep<11>2014
17:43 Nov 09, 2022
Jkt 259001
The ISUDCC is open to the public and
members of the public can attend the
meeting via telephone or webcast only,
and not in person. Agenda with call-in
information will be posted on the
SAMHSA website prior to the meeting
at: https://www.samhsa.gov/about-us/
advisory-councils/meetings. The
meeting will include information on
establishing ISUDCC working groups,
and their deliverables in support for the
mission and work of the Committee;
federal advances to address challenges
in substance use disorder (SUD); and
non-federal advances to address
challenges in SUD.
Committee Name: Interdepartmental
Substance Use Disorders Coordinating
Committee (ISUDCC).
DATES: December 20, 2022, 11:30 a.m.–
1:30 p.m. EST/Open.
ADDRESSES: The meeting will be held
virtually.
The meeting can be accessed via
Zoom.
FOR FURTHER INFORMATION CONTACT:
Tracy Goss, ISUDCC Designated Federal
Officer, Substance Abuse and Mental
Health Services Administration, 5600
Fishers Lane, 13E37B, Rockville, MD
20857; telephone: 240–276–0759; email:
Tracy.Goss@samhsa.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Background and Authority
The Interdepartmental Substance Use
Disorders Coordinating Committee is
required under Section 7022 of the
Substance Use-Disorder Prevention that
Promotes Opioid Recovery and
Treatment for Patients and Communities
Act (SUPPORT Act, Pub. L. 115–271) to
accomplish the following duties: (1)
identify areas for improved coordination
of activities, if any, related to substance
use disorders, including research,
services, supports, and prevention
activities across all relevant federal
agencies; (2) identify and provide to the
Secretary recommendations for
improving federal programs for the
prevention and treatment of, and
recovery from, substance use disorders,
including by expanding access to
prevention, treatment, and recovery
services; (3) analyze substance use
disorder prevention and treatment
strategies in different regions of and
populations in the United States and
evaluate the extent to which federal
substance use disorder prevention and
treatment strategies are aligned with
State and local substance use disorder
prevention and treatment strategies; (4)
make recommendations to the Secretary
regarding any appropriate changes with
respect to the activities and strategies
described in items (1) through (3) above;
PO 00000
Frm 00067
Fmt 4703
Sfmt 4703
67921
(5) make recommendations to the
Secretary regarding public participation
in decisions relating to substance use
disorders and the process by which
public feedback can be better integrated
into such decisions; and (6) make
recommendations to ensure that
substance use disorder research,
services, supports, and prevention
activities of the Department of Health
and Human Services and other federal
agencies are not unnecessarily
duplicative.
Not later than one year after the date
of the enactment of this Act, and
annually thereafter for the life of the
Committee, the Committee shall publish
on the internet website of the
Department of Health and Human
Services, which may include the public
information dashboard established
under section 1711 of the Public Health
Service Act, as added by section 7021,
a report summarizing the activities
carried out by the Committee pursuant
to subsection (e), including any findings
resulting from such activities.
II. Membership
This ISUDCC consists of federal
members listed below or their
designees, and non-federal public
members.
Federal Membership: Members
include, The Secretary of Health and
Human Services; The Attorney General
of the United States; The Secretary of
Labor; The Secretary of Housing and
Urban Development; The Secretary of
Education; The Secretary of Veterans
Affairs; The Commissioner of Social
Security; The Assistant Secretary for
Mental Health and Substance Use; The
Director of National Drug Control
Policy; representatives of other Federal
agencies that support or conduct
activities or programs related to
substance use disorders, as determined
appropriate by the Secretary.
Non-federal Membership: Members
include, 17 non-federal public members
appointed by the Secretary, representing
individuals who have received
treatment for a diagnosis of a substance
use disorder; directors of State
substance use agencies; representatives
of leading research, advocacy, or service
organizations for adults with substance
use disorder; physicians, licensed
mental health professionals, advance
practice registered nurses, and
physician assistants, who have
experience in treating individuals with
substance use disorders; substance use
disorder treatment professionals who
provide treatment services at a certified
opioid treatment program; substance use
disorder treatment professionals who
have research or clinical experience in
E:\FR\FM\10NON1.SGM
10NON1
]]>Agencies
[Federal Register Volume 87, Number 217 (Thursday, November 10, 2022)]
[Notices]
[Pages 67920-67921]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-24610]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Charter Renewal of the Advisory Committee on Blood and Tissue
Safety and Availability
AGENCY: Office of the Assistant Secretary for Health, Office of the
Secretary, Department of Health and Human Services.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Department of Health and Human Services is hereby giving
notice that the charter for the Advisory Committee on Blood and Tissue
Safety and Availability (ACBTSA) has been renewed.
FOR FURTHER INFORMATION CONTACT: James Berger, Designated Federal
Officer for the TBDWG; Office of Infectious Disease and HIV/AIDS
Policy, Office of the Assistant Secretary for Health, Department of
Health and Human Services, Tower Building, 1101 Wootton Parkway,
Rockville, MD 20852. Phone: (202) 795-7608. Email: [email protected].
SUPPLEMENTARY INFORMATION: The ACBTSA is a non-discretionary federal
advisory committee. The ACBTSA is authorized under 42 U.S.C. 217a,
Section 222 of the Public Health Service (PHS) Act, as amended. The
Committee is governed by the provisions of the Federal Advisory
Committee Act (FACA), Public Law 92-463, as amended (5 U.S.C. App),
which sets forth standards for the formation and use of advisory
committees. The ACBTSA advises, assists, consults with, and makes
policy recommendations to the Secretary, through the Assistant
Secretary for Health, regarding broad responsibilities related to the
safety of blood, blood products, tissues, and organs. For solid organs
and blood stem cells, the Committee's work is limited to policy issues
related to donor derived
[[Page 67921]]
infectious disease complications of transplantation.
To carry out its mission, the ACBTSA provides advice to the
Secretary through the Assistant Secretary for Health on a range of
policy issues which includes: (1) identification of public health
issues through surveillance of blood and tissue safety issues with
national biovigilance data tools; (2) identification of public health
issues that affect availability of blood, blood products, and tissues;
(3) broad public health, ethical, and legal issues related to the
safety of blood, blood products, and tissues; (4) the impact of various
economic factors (e.g., product cost and supply) on safety and
availability of blood, blood products, and tissues; (5) risk
communications related to blood transfusion and tissue transplantation;
and (6) identification of infectious disease transmission issues for
blood, organs, blood stem cells and tissues.
On September 29, 2022, the Secretary approved for the ACBTSA
charter to be renewed. The new charter was filed with the appropriate
Congressional committees and the Library of Congress on October 9,
2022. Renewal of the Committee's charter gives authorization for the
Committee to continue to operate until October 9, 2024.
A copy of the ACBTSA charter is available on the Committee's
website at https://www.hhs.gov/oidp/advisory-committee/blood-tissue-safety-availability/charter/.
Dated: November 2, 2022.
James J. Berger,
DFO, Advisory Committee on Blood and Safety and Availability, Office of
HIV/AIDS and Infectious Disease Policy.
[FR Doc. 2022-24610 Filed 11-9-22; 8:45 am]
BILLING CODE 4150-41-P
